来源:福布斯 医药创新这个赛道,辉瑞、强生、阿斯利康、诺和诺德等国际巨头林立,十年磨一剑也未必可行。 康方生物有限公司创始人、董事长夏瑜向福布斯中国表示:“中国医药创新真正的崛起,必须依靠自身实力,培育创新氛围,打造创新体系,实现创新成果突破。从全球行业发展的商业模式来看,买买买的模式一点问题都没有,但像辉瑞、强生、阿斯利康、诺和诺德这类医药行业领军巨头企业,在国际上有一席之地的医药企业,...
Source Link财经自媒体2021-07-27
来源:福布斯 医药创新这个赛道,辉瑞、强生、阿斯利康、诺和诺德等国际巨头林立,十年磨一剑也未必可行。 康方生物有限公司创始人、董事长夏瑜向福布斯中国表示:“中国医药创新真正的崛起,必须依靠自身实力,培育创新氛围,打造创新体系,实现创新成果突破。从全球行业发展的商业模式来看,买买买的模式一点问题都没有,但像辉瑞、强生、阿斯利康、诺和诺德这类医药行业领军巨头企业,在国际上有一席之地的医药企业,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email:uservice@ttm.financial